These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2199835)

  • 1. Waking up to an OTA, OIG morning. Reports show need for accurate administrative cost survey. Office of Technology Assessment. Office of the Inspector General.
    Hull A
    Nephrol News Issues; 1990 Jul; 4(7):11, 35, 45. PubMed ID: 2199835
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant erythropoietin. The effect of the marketplace on socialized patient care.
    Besarab A; Erslev AJ
    ASAIO J; 1993; 39(2):85-6. PubMed ID: 8324265
    [No Abstract]   [Full Text] [Related]  

  • 4. Report from the University Healthsystem Consortium.
    Int J Technol Assess Health Care; 1999; 15(2):437-8. PubMed ID: 10507201
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin & ESRD payments: a promising policy outcome?
    Roe W
    Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicare and Medicaid programs; program integrity--HCFA. Final rule.
    Fed Regist; 1986 Sep; 51(189):34786-8. PubMed ID: 10301243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Office of Inspector General; Medicare program; prospective payment system for hospital outpatient services. Health Care Financing Administration (HCFA), HHS, and Office of Inspector General (OIG), HHS. Final rule with comment period.
    Fed Regist; 2000 Apr; 65(68):18434-82. PubMed ID: 11010643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of growth of interventional techniques in managing chronic pain in the Medicare population: a 10-year evaluation from 1997 to 2006.
    Manchikanti L; Singh V; Pampati V; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(1):9-34. PubMed ID: 19165296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Office of Inspector General U.S. Department of Health and Human Services. An overview.
    Federgreen WR
    J Fla Med Assoc; 1993 Apr; 80(4):236-40. PubMed ID: 8505613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HCFA's revised billing instructions for kinetic modeling and recirculation tests.
    Rosenthal AF; Mahlke KF
    Nephrol News Issues; 1998 Feb; 12(2):12. PubMed ID: 9526364
    [No Abstract]   [Full Text] [Related]  

  • 11. Hospital survey process is evaluated. Two-year assessment by the Office of Inspector General.
    Health Care Food Nutr Focus; 2000 Jan; 16(5):7. PubMed ID: 10788013
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicare demonstration project creeping to the starting line.
    Capitation Manag Rep; 2004 Oct; 11(10):109-11. PubMed ID: 15566118
    [No Abstract]   [Full Text] [Related]  

  • 13. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 14. ESA payment changes: chasing a moving target.
    Sargent JA
    Nephrol News Issues; 2008 Jan; 22(1):36-7. PubMed ID: 18271437
    [No Abstract]   [Full Text] [Related]  

  • 15. What does the future hold for hospice in the present envirornment?
    Neigh JE
    Caring; 2008 Nov; 27(11):6-7. PubMed ID: 19068869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the Medicare and Medicaid programs.
    Health Care Financ Rev Stat Suppl; 1999; ():1-348. PubMed ID: 12847762
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicare HMOs reveal unique contracting strategies for new ESRD risk demonstration.
    Public Sect Contract Rep; 1997 May; 3(5):74-6. PubMed ID: 10174874
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges in establishing a clinically and scientifically robust epoetin policy.
    Cotter DJ
    Clin Nephrol; 2004 Jul; 62(1):69-70. PubMed ID: 15267018
    [No Abstract]   [Full Text] [Related]  

  • 19. What price success?
    Tecnologica; 1996 Nov; ():1-6. PubMed ID: 10179816
    [No Abstract]   [Full Text] [Related]  

  • 20. Can evidence drive the development of a sound national EPO reimbursement policy?
    Wish JB
    Am J Kidney Dis; 2003 Jan; 41(1):254-8. PubMed ID: 12500246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.